Mono Pharmacare Limited

As of September 30, 2025, Mono Pharmacare Limited carries a market capitalization of 389.59M, placing it among publicly traded companies globally. Its enterprise value stands at 927.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2025, Mono Pharmacare Limited has 17.67M shares outstanding.

These figures are as of September 30, 2025.

As of September 30, 2025, Mono Pharmacare Limited maintains a current ratio of 1.92, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2025.

As of the close on October 9, 2026, Mono Pharmacare Limited's stock has declined approximately 58.99% over the past 52 weeks. The 50-day moving average sits at 9.24, while the 200-day moving average is 14.60.

As of September 30, 2025, Mono Pharmacare Limited holds 12.40M in cash and equivalents against 549.96M in total debt, resulting in a net debt position of 537.56M. Total book value stands at 312.20M, with working capital of 567.79M providing operational flexibility.